scholarly journals Single Cell Transcriptomic Analysis of Pancreatic β Cell Development and Differentiation from Pluripotent Stem Cells

2019 ◽  
Vol 3 (3) ◽  
pp. 1-1
Author(s):  
Chunhui Xie ◽  
◽  
Lillian Ye ◽  
Yeh-Chuin Poh ◽  
George Harb ◽  
...  
2020 ◽  
Vol 37 ◽  
pp. 100982
Author(s):  
Ye Feng ◽  
Wei-Lin Qiu ◽  
Xin-Xin Yu ◽  
Yu Zhang ◽  
Mao-Yang He ◽  
...  

Stem Cells ◽  
2018 ◽  
Vol 37 (1) ◽  
pp. 33-41 ◽  
Author(s):  
Diego Balboa ◽  
Jonna Saarimäki-Vire ◽  
Timo Otonkoski

Author(s):  
Natanya Kerper ◽  
Sudipta Ashe ◽  
Matthias Hebrok

2014 ◽  
Vol 19 (2) ◽  
pp. 162-168 ◽  
Author(s):  
Riccardo Calafiore ◽  
Pia Montanucci ◽  
Giuseppe Basta

2021 ◽  
Vol 12 ◽  
Author(s):  
Matthew N. George ◽  
Karla F. Leavens ◽  
Paul Gadue

A mechanistic understanding of the genetic basis of complex diseases such as diabetes mellitus remain elusive due in large part to the activity of genetic disease modifiers that impact the penetrance and/or presentation of disease phenotypes. In the face of such complexity, rare forms of diabetes that result from single-gene mutations (monogenic diabetes) can be used to model the contribution of individual genetic factors to pancreatic β-cell dysfunction and the breakdown of glucose homeostasis. Here we review the contribution of protein coding and non-protein coding genetic disease modifiers to the pathogenesis of diabetes subtypes, as well as how recent technological advances in the generation, differentiation, and genome editing of human pluripotent stem cells (hPSC) enable the development of cell-based disease models. Finally, we describe a disease modifier discovery platform that utilizes these technologies to identify novel genetic modifiers using induced pluripotent stem cells (iPSC) derived from patients with monogenic diabetes caused by heterozygous mutations.


Sign in / Sign up

Export Citation Format

Share Document